The myc family of genes plays an important role in several cellular processes including proliferation, apoptosis, dierentiation, and transformation. B-myc, a relatively new and largely unstudied member of the myc family, encodes a protein that is highly homologous to the N-terminal transcriptional regulatory domain of cMyc. Here, we show that high level B-myc expression is restricted to speci®c mouse tissues, primarily hormonally-controlled tissues, with the highest level of expression in the epididymis. We also report the identi®cation of the endogenous B-Myc protein from mouse tissues. Like other Myc family proteins, B-Myc is a short-lived nuclear protein which is phosphorylated on residues Ser-60 and Ser-68. Rapid proteolysis of B-Myc occurs via the ubiquitin-proteasome pathway. Finally, we found that overexpression of B-Myc signi®cantly slows the growth of Rat 1a ®broblasts and COS cells suggesting B-Myc functions as an inhibitor of cellular proliferation.
Introduction
Many studies have demonstrated a fundamental role for myc family genes in the control of cellular proliferation, dierentiation, apoptosis and tumorigenesis (Depinho et al., 1991; Marcu et al., 1992; Henriksson and Luscher, 1996) . The myc family includes three highly related genes, c-myc, N-myc and L-myc, which are thought to have similar molecular functions and all three genes have documented oncogenic potential (Depinho et al., 1991) . The best studied myc gene, c-myc, encodes a short-lived nuclear phosphoprotein which is a critical and potent promoter of cellular proliferation. Expression of c-myc is induced by mitogenic stimuli and constitutive c-myc expression inhibits exit from the cell cycle and prevents dierentiation (Marcu et al., 1992; Henriksson and Luscher, 1996) . The deregulated expression of c-myc appears to contribute to the pathogenesis of a wide variety of human cancers. The c-Myc protein is a transcription factor of the helix ± loop ± helix/leucine zipper class. Two regions of c-Myc are critical for biological function, the N-terminal transcriptional regulatory domain (TRD) and the C-terminal basic region ± helix ± loop ± helix/leucine zipper (bHLH/LZ) DNA binding domain. c-Myc can activate the transcription of speci®c E-box-containing genes as a heterodimeric complex with its partner protein, Max, and additionally can repress the transcription of speci®c genes (Henriksson and Luscher, 1996; Facchini and Penn, 1998) . c-Myc is thought to exert its biological eects through the regulation of target genes involved with cellular proliferation.
A more recently described myc family member, Bmyc, has remained less well characterized. B-myc was ®rst cloned from a rat genomic library by homology to c-myc (Ingvarsson et al., 1988a) . Since then, only murine B-myc has additionally been cloned (Asker et al., 1995) ; however, B-myc appears to be conserved across mammalian species, including humans, based on Southern blot analysis (Ingvarsson et al., 1988a) . The B-myc gene contains a single coding exon which is highly homologous to c-myc exon 2 and expresses a 1.3 kb mRNA (Ingvarsson et al., 1988a; Asker et al., 1989) . B-myc expression was detected in several rat tissues including lung, kidney, heart, intestine, spleen, liver and thymus with the highest expression detected in the brain (hence B-myc). In contrast to c-myc, which is down-regulated in most adult tissues, B-myc was found to be expressed at similar levels in fetal and adult rat tissues (Ingvarsson et al., 1988a) .
B-myc encodes a 170 amino acid protein (murine BMyc) that is 68% identical to the N-terminal region of c-Myc (Asker et al., 1995) , which contains the c-Myc TRD (Figure 1) . B-Myc contains both`Myc boxes', MBI and II. MBI and II are regions highly conserved between Myc family members, as well as between species, and are thought to be important for Myc function. The homology with c-Myc falls o in the Cterminus of B-Myc with the C-terminal 14 amino acids being unique. B-Myc is unusual among Myc family members in that it is relatively small and lacks a region corresponding to the bHLH/LZ domain required for dimerization with Max and sequence-speci®c DNA binding. B-Myc has been shown to inhibit both the transactivation and transformation ability of c-Myc suggesting that B-Myc may act as an antagonist of Myc function (Resar et al., 1993) . However, the biological role of B-Myc has yet to be established.
The lack of knowledge concerning the expression, protein characteristics, and function of B-myc prompted our current analysis. Here, we report that, in addition to the brain, B-myc is expressed at high levels in several hormonally-regulated adult mouse tissues with highest expression detected in the epididymis. We also report the identi®cation of the endogenous B-Myc protein. We show that, like c-Myc, B-Myc is a short-lived nuclear phosphoprotein which is degraded by the ubiquitin-proteasome pathway. Finally, we demonstrate that, counter to c-Myc, B-Myc inhibits cellular proliferation.
Results

Tissue-specific expression of B-myc
Analysis of a gene's expression pattern can often help to reveal its normal physiological function. A previous study had shown that B-myc is expressed at low levels in several rat tissues with relatively high expression in the brain; however, only eight tissues were examined (Ingvarsson et al., 1988a) . To more thoroughly characterize the expression pattern of B-myc, we analysed B-myc expression in 24 tissues of the adult mouse by Northern blot analysis. As shown in Figure  2a , B-myc mRNA was detected at relatively high levels in several speci®c tissues, especially hormonally-controlled tissues, including the adrenal, pituitary, ovary, uterus, prostate, and brain with the highest levels detected in the epididymis. Relatively high B-myc levels, comparable to the brain, ovary and uterus, were additionally detected in the hypothalamus and mammary gland (data not shown). Comparison with the expression pattern of c-myc (Figure 2b ) revealed that B-myc and c-myc are expressed together in several tissues including the adrenal, ovary, uterus, and prostate. However, c-myc levels are low in the epididymis and brain where B-myc expression is high. Conversely, B-myc levels are low or undetectable in some tissues, such as the thymus and intestines, with high c-myc expression. B-myc showed a similar expression pattern in adult rat tissues with highest expression detected in the epididymis and pituitary (data not shown). These results demonstrate that Bmyc expression is distinct from c-myc and that high Bmyc expression is restricted predominantly to hormonally-controlled tissues.
To further examine B-myc mRNA expression in speci®c cell types, several pituitary cell lines were analysed by Northern blot, including aT3-1, an undierentiated gonadotrope; LbT2, a dierentiated gonadotrope; GH3 somatotrope/lactotrope; and the ®broblast cell line NIH3T3. B-myc expression was higher in the pituitary cell lines, LbT2 and GH3, which are characterized as having a dierentiated phenotype based on their expression of cell-speci®c peptide hormone genes (Tashjian et al., 1970; Turgeon et al., 1996) , compared with the undierentiated cell line, aT3-1 (Figure 3a ). There was no detectable expression of B-myc in NIH3T3 ®broblasts. In contrast to B-myc, c-myc expression was high in ®broblasts with less expression in the pituitary cells (Figure 3b ).
Identification of endogenous B-Myc protein
It has been shown that B-myc, when expressed ectopically, encodes a 26 kD protein. (Asker et al., 1995) . Endogenous B-Myc protein, however, has not previously been identi®ed, leading to the suggestion that B-myc could merely be a pseudogene (Henriksson Figure 2 Northern blot analysis of B-myc and c-myc mRNA expression in adult mouse tissues. Ten mg samples of total RNA isolated from the indicated adult mouse tissues were resolved on a 1% agarose-formaldehyde gel, transferred to nylon, and hybridized sequentially to 32 P-labeled probes as described in Materials and methods for (a) B-myc; (b) c-myc and (c) 18S rRNA. The positions of 18S and 28S rRNAs are indicated at left. Right panels represent separate Northern blots processed under the same conditions as described above and Luscher, 1996) . To facilitate the identi®cation and characterization of B-Myc, a B-Myc-speci®c antibody was generated. The C-terminal 50 amino acids of murine B-Myc fused to GST was used to raise rabbit polyclonal antiserum (anti-B-Myc50C) which was then anity puri®ed. The C-terminus of B-Myc was chosen as the immunogen as it contains the region of lowest homology with c-Myc (Asker et al., 1995) . To test the speci®city of anti-B-Myc50C, the antibody was used in immunoprecipitation analysis of in vitro translated BMyc and c-Myc. As shown in Figure 4a , antiMycN100, raised against the N-terminal 100 amino acids of c-Myc, immunoprecipitated both c-Myc and B-Myc. In contrast, anti-B-Myc50C eciently recognized 26 kD B-Myc but did not recognize c-Myc, indicating that the antibody is speci®c for B-Myc.
In order to identify endogenous B-Myc protein, we ®rst examined adult mouse epididymal tissue, where Bmyc mRNA levels were found to be the highest ( Figure  1a) , by Western blot analysis using anti-B-Myc50C. COS-7 cells transiently transfected with a B-Myc expression plasmid, CMV-B-Myc, were used as a control. As shown in Figure 4b , a 26 kD protein which comigrated with overexpressed B-Myc from COS-7 cells was identi®ed in the epididymis. Several additional adult mouse tissues were analysed for BMyc protein expression by Western blotting ( Figure  4c) . B-Myc was highest in the epididymis and was also easily detected in the hypothalamus, pituitary, uterus, and ovary. B-Myc expression was low in the testis and undetectable in the heart. Thus, the pattern of protein expression observed closely correlates with B-myc mRNA expression indicating that the identi®ed 26 kD protein is indeed B-Myc.
Characterization of B-Myc protein
It has long been known that c-myc encodes a shortlived nuclear phosphoprotein (Hann and Eisenman, 1984) . The B-Myc protein, however, has remained largely uncharacterized. In order to perform initial characterization of B-Myc, CMV-B-Myc was stably expressed in COS-7 cells. To determine the subcellular localization of B-Myc, a biochemical fractionation was performed. After metabolic labeling with 35 S-methionine/cysteine, the cells were fractionated into cytoplasmic (C), detergent-soluble nuclear (nucleoplasmic; NP) and detergent-insoluble nuclear (nuclear; N) fractions followed by immunoprecipitation analysis using antiMycN100, which recognizes both c-Myc and B-Myc. As shown in Figure 5a , endogenous c-Myc was mainly associated with the nuclear and nucleoplasmic fractions (lanes 2 and 3), as has been previously observed (Hann and Eisenman, 1984) . The majority of B-Myc was associated with the nucleoplasmic fraction ( Figure 5a , lane 2) while a smaller proportion of B-Myc was associated with the cytoplasmic fraction (lane 1). Thus, although it lacks a discernible nuclear localization signal, B-Myc, like c-Myc, appears to be mainly localized to the nucleus.
To determine if B-Myc is a short-lived protein, a pulse-chase analysis was performed. As shown in Figure 5b , B-Myc is rapidly degraded in vivo with a half-life of approximately 25 min, which is comparable to the short half-life (usually 20 ± 30 min) of cMyc proteins (Hann and Eisenman, 1984; Spotts et al., 1997) . A similar rate of turnover was observed for endogenous B-Myc from LbT2 cells (data not shown). Several in vivo phosphorylation sites have been de®ned in the N-terminal domain of c-Myc including Thr-58, Ser-62, and Ser-71 (Lutterbach and Hann, 1994) , which are conserved in B-Myc. To determine if B-Myc is also phosphorylated, CMV-B-Myc was transiently transfected into COS-7 cells and 48 h after transfection, the cells were metabolically labeled with 32 P-orthophosphate and subjected to immunoprecipitation with anti-B-Myc50C. Anti-B-Myc50C speci®cally recognized a 32 P-labeled protein which migrated at 26 Kd (data not shown) indicating that B-Myc is indeed phosphorylated. To determine if BMyc is phosphorylated at similar sites compared with c-Myc, 2-D thermolytic phosphopeptide mapping analysis of immunoprecipitated B-Myc was performed. As shown in Figure 5c , the peptide map of B-Myc revealed three major phosphopeptides (labeled A ± C). Peptides A and B migrated similarly to thermolytic peptides of c-Myc containing phosphorylation at Ser-71 and Ser-62 respectively (Lutterbach and Hann, 1994) . To determine whether the corresponding sites in B-Myc, Ser-68 and Ser-60, are phosphorylated, both were mutagenized individually to alanine and the mutated B-Myc proteins were analysed by phosphopeptide mapping as above. An alanine substitution at Ser-60 (S60A) resulted in the disappearance of peptide B (Figure 5c ) indicating that B-Myc is phosphorylated at Ser-60. An alanine substitution at Ser-68 (S68A) resulted in the loss of both peptides A and C ( Figure 5c ) indicating that both peptides contain Ser-68 phosphorylation and that Ser-68 is the major site of phosphorylation in B-Myc. Although Thr-58 of c-Myc is conserved in B-Myc (Thr-56), B-Myc did not appear to contain a phosphopeptide corresponding to phosphorylation at Thr-56, which should migrate similarly to the corresponding thermolytic phosphopeptide of c-Myc (Lutterbach and Hann, 1994) due to the high homology in this region. These results demonstrate that B-Myc is phosphorylated in vivo at similar sites compared with c-Myc and suggest B-Myc may be regulated by similar kinases. Peptides were separated on thin-layer chromatography plates, in the ®rst dimension by electrophoresis at pH 1.9, and in the second dimension by ascending chromatography as described in Materials and methods. Arrowheads indicate the loading origin
Degradation of B-Myc by the ubiquitin-proteasome pathway
We and others have previously shown that the c-Myc protein is rapidly degraded by the ubiquitin-proteasome pathway (Gross-Mesilaty et al., 1998; Salghetti et al., 1999; Gregory and Hann, 2000) . In this pathway, protein substrates are conjugated to ubiquitin and, upon multiubiquitination, are targeted for rapid proteolysis by the 26S proteasome (Ciechanover, 1994) . As B-myc has a similar short half-life compared with c-Myc, we sought to determine whether B-Myc is also a substrate of the ubiquitin-proteasome pathway. We ®rst determined whether B-Myc degradation is dependent upon the activity of the proteasome by utilizing the potent proteasome inhibitor, ALLN (Rock et al., 1994) . COS-7 cells overexpressing B-Myc were treated with ALLN or with the solvent (DMSO) as a control and subjected to pulse-chase analysis. As shown in Figure 6a , degradation of B-Myc was markedly inhibited by treatment with ALLN. To determine if B-Myc is a substrate for ubiquitination, COS-7 cells were transiently transfected with CMV-BMyc and an expression plasmid encoding HA epitopetagged ubiquitin (HA-Ub). Forty-six hours after transfection, cells were left untreated or treated with ALLN for 2 h. B-Myc was immunoprecipitated using anti-B-Myc50C and subjected to Western blotting for the HA epitope. As shown in Figure 6b , HAimmunoreactive upper molecular weight bands were observed only in the B-Myc immunoprecipitate derived from ALLN-treated cells cotransfected with B-Myc and HA-Ub indicating that B-Myc is ubiquitinated. Taken together, these results suggest that B-Myc is degraded by the ubiquitin-proteasome pathway in vivo.
Effect of B-Myc on cellular proliferation
Our previous studies demonstrated that c-Myc proteins stimulate the proliferation of Rat 1a ®broblasts when overexpressed (Xiao et al., 1998) . To determine if BMyc has an eect on proliferation, stable Rat 1a ®broblast cell lines which overexpress B-Myc were generated by viral infection and used in cell growth assays. Expression of B-Myc in these cell lines was veri®ed by immunoprecipitation analysis (Figure 7a ). As shown in Figure 7b , cell lines expressing B-Myc grew signi®cantly slower relative to uninfected Rat 1a cells and Rat 1a cells infected with empty vector (pBabe). In order to determine if B-Myc inhibits the growth of another cell type, a COS-7 cell line stably transfected with CMV-B-Myc was examined. COS-7 cells expressing B-Myc grew signi®cantly slower than untransfected COS-7 cells (Figure 7c ). These results suggest that, in contrast to c-Myc's ability to promote cellular proliferation, B-Myc acts as an inhibitor of proliferation.
Discussion
Expression of B-myc in hormonally-regulated tissues
Previous studies have shown that c-myc is ubiquitously expressed in developing tissues; however, in adult tissues, c-myc expression is more restricted and generally correlates with proliferation (Zimmerman et al., 1986; Ingvarsson et al., 1988a; Schmid et al., 1989; Semsei et al., 1989) . In contrast, B-myc was previously found to be rather ubiquitously expressed in adult rat tissues based on a limited survey (Ingvarsson et al., 1988a) . In agreement with these previous studies, we found c-myc expression in the adult mouse is high in the thymus and intestines and low in nonproliferative tissues such as the brain, while B-myc expression is high in the brain, lung and large intestine relative to other tissues. A more thorough examination revealed that high B-myc expression is restricted to speci®c, mainly hormonally-controlled tissues. We found that B-myc is most highly expressed in the epididymis, followed by the pituitary. Relatively high B-myc levels were additionally found in the ovary, uterus, adrenal, prostate, and mammary gland, comparable to the levels found in the brain. An examination of rainbow trout tissues also found high level expression of a 1.4 kb putative B-myc transcript in the pituitary (Panno and McKeown, 1993) . The ®nding that BMyc can inhibit cellular proliferation, as discussed below, and can inhibit the transactivating and transforming activities of c-Myc (Resar et al., 1993) indicates that B-Myc has a role in modulating Figure 6 Degradation of B-Myc by the ubiquitin-proteasome pathway. (a) COS-7 cells were transiently transfected with CMV-B-Myc. Forty-six hours post-transfection, the cells were treated with the proteasome inhibitor ALLN (100 mM) or the solvent DMSO for 2 h followed by pulse-chase analysis as described in Figure 5b ; DMSO or ALLN was included throughout the pulsechase. B-Myc was immunoprecipitated using anti-B-Myc50C and separated by 15% SDS ± PAGE. (b) COS-7 cells were transiently transfected with 2 mg of CMV-B-Myc and/or 4 mg of CMV-HAUb (encoding HA-tagged ubiquitin). Forty-six hours posttransfection, the cells were left untreated or treated with ALLN (100 mM) for 2 h. Cell lysates were subjected to immunoprecipitation using anti-B-Myc50C. Immune complexes were separated by 12.5% SDS ± PAGE followed by Western blot analysis using anti-HA (12CA5) to detect B-Myc-HA-ubiquitin conjugates. The blot was stripped and reprobed with anti-B-Myc50C to verify B-Myc expression. Numbers at left (in kilodaltons) indicate positions of molecular size markers. Asterisks indicate nonspeci®c background bands proliferation. This may be especially important in tissues which coexpress B-Myc and c-Myc, such as the ovary, uterus, prostate, mammary gland and adrenal; however, whether B-Myc and c-Myc are coexpressed in the same cells in these tissues has yet to be determined.
Although high tissue-speci®c expression of a transcriptional regulatory protein in such diverse tissues as the epididymis and brain seems unusual, it is not unprecedented. For example, the transcription factor, PEA3, is also expressed highly in the mouse epididymis and brain (Xin et al., 1992) . However, unlike B-myc, PEA3 is downregulated following dierentiation of embryonal carcinoma cells, is expressed in ®broblasts (Xin et al., 1992) , and is regulated by mitogens (O'Hagan et al., 1996) . A possible role for B-Myc in dierentiation is indicated by the observation that Bmyc expression was much lower in the undierentiated pituitary cell line, aT3-1 compared to the more dierentiated pituitary lines, LbT2 and GH3. Also, B-myc mRNA is strongly induced when the trophectoderm lineage, the ®rst embryonic cell lineage to undergo dierentiation, is beginning to dierentiate (Domashenko et al., 1997) suggesting a role in very early dierentiative events. B-Myc most likely does not have a general role in dierentiation or proliferation, since B-myc expression was not regulated upon induction of dierentiation or by serum starvation of the F9 embryonal carcinoma cell line (Ingvarsson et al., 1988b) . Furthermore, preliminary analysis of NMuMG mouse mammary gland epithelial cells showed that B-myc levels were not signi®cantly altered by serum stimulation (Xiao and Hann, unpublished observations) . Although B-myc expression does not appear to be mitogen-regulated, it does appear to be under hormonal control. B-myc expression in the epididymis was found to be highly regionalized and highly dependent on the presence of androgens and testicular factors (Cornwall et al. manuscript submitted). Taken together, these results suggest a specialized role for B-Myc in speci®c, mainly hormonally-regulated tissues.
To investigate the expression of B-Myc protein in vivo we generated a rabbit polyclonal antiserum against the C-terminal third of the protein which has the least homology to c-myc. The resulting antibody was indeed B-Myc speci®c and allowed us to identify the endogenous B-Myc protein in tissues, eliminating previous concerns that B-myc may not be a functional gene. The endogenous protein migrated as predicted and appeared identical to the 26 kD protein expressed from the B-myc cDNA. The pattern of B-Myc protein expression was similar to the B-myc mRNA in the tissues examined; however, the mRNA expression in the epididymis appeared much greater than the protein expression when compared to other tissues. This suggests that there may be a dierence in the translational regulation or protein turnover of B-Myc in the epididymis compared to other tissues. In addition, the B-Myc protein appeared as a doublet in some tissue samples, such as the epididymis and uterus, and as a single band in others, such as the hypothalamus and pituitary. This suggests that the protein is dierentially modi®ed, perhaps by hyperphosphorylation, in a tissue-speci®c manner. Taken together, our results suggest that B-myc mRNA and protein expression may be regulated at several levels.
B-Myc is a short-lived nuclear phosphoprotein
The Myc family proteins, c-Myc, N-Myc, and L-Myc, are highly related short-lived nuclear phosphoproteins (Henriksson and Luscher, 1996) . B-Myc is unique compared with the other Myc family members; it lacks the C-terminal motifs which mediate their nuclear localization, dimerization with Max, and DNA bind- , were generated by transfection of CMV-B-Myc as described in Materials and methods. COS(B-Myc) and untransfected COS-7 cells were subjected to growth curve analysis as described in (b) ing. Despite the lack of a recognized nuclear localization signal, we found by using cellular fractionation analysis that B-Myc is mainly nuclear. The nuclear localization of B-Myc, however, appears to dier from that of c-Myc, as B-Myc was easily extracted from the nucleus with detergent (0.5% Triton X-100, 0.1% DOC) indicating B-Myc is nucleoplasmic, i.e. not tightly associated with subnuclear structures. These results are consistent with those of Asker et al. (1995) who used immuno¯uorescence analysis to show predominant nuclear localization of ectopically expressed B-Myc. Furthermore, immunohistochemical analysis demonstrated nuclear localization of B-Myc in epithelial cells of the mouse epididymis (Cornwall et al., manuscript submitted). Since B-Myc lacks a nuclear localization signal, it is likely that it enters the nucleus complexed to another cellular factor(s). Assuming that B-Myc functions in the nucleus, the regulation of this factor would oer another means to modulate the activity of B-Myc.
In this report we have shown that B-Myc, like other Myc family proteins, is rapidly degraded in vivo with a half-life of approximately 25 min. Although the B-myc transcript is more stable (half-life of 3.5 to 6 h; Cornwall et al. manuscript submitted; Ingvarsson et al., 1988b) , the short half-life of the B-Myc protein would allow relatively tight regulation of B-Myc expression. It has recently been demonstrated that rapid proteolysis of c-Myc is mediated by the ubiquitin-proteasome pathway (Gross-Mesilaty et al., 1998; Salghetti et al., 1999; Gregory and Hann, 2000) . Furthermore, the N-terminal domain of c-Myc (amino acids 1 ± 158) was found to be required for ecient cMyc ubiquitination and degradation (Gregory and Hann, 2000) . We have now shown that B-Myc is likewise degraded by the ubiquitin pathway. As B-Myc is highly homologous to the c-Myc N-terminal domain, this suggests this region of c-Myc contains sucient sequence information to target the protein for rapid ubiquitin-mediated proteolysis. Although a PEST motif in c-Myc is also essential for its rapid degradation (Gregory and Hann, 2000) , B-Myc contains no such motif, suggesting that a PEST motif is only necessary for the degradation of larger Myc proteins (Gregory and Hann, 2000) . It has been hypothesized that phosphorylation may play a role in facilitating rapid c-Myc proteolysis. We found that substitution of Thr-58 with nonphosphorylatable alanine modestly stabilizes the c-Myc protein (1.6 ± 1.7-fold, 1999; Gregory and Hann, 2000) while others found a more substantial eect (Salghetti et al., 1999) . However, the homologous site in B-Myc, Thr-56, does not appear to be phosphorylated suggesting that phosphorylation of this site in B-Myc is not essential for rapid degradation.
c-Myc is a substrate for phosphorylation at ®ve Nterminal sites, including Thr-58, Ser-62, and Ser-71 (Lutterbach and Hann, 1994, 1997) . Furthermore, there is substantial evidence that phosphorylation of these sites plays a role in regulating c-Myc's various biological activities (Henriksson et al., 1993; Pulverer et al., 1994; Noguchi et al., 1999; Change et al., 2000) . Through phosphopeptide mapping analysis, we've now shown that B-Myc is phosphorylated at Ser-60 and Ser-68, homologous to Ser-62 and Ser-71 of c-Myc, with Ser-68 being the major phosphorylation site. Interestingly, mutation of Ser-68 resulted in the loss of both major thermolytic phosphopeptides, peptides A and C, in B-Myc peptide maps suggesting that both peptides contain Ser-68 phosphorylation. Peptide A migrated very similarly to the corresponding phosphoSer-71 containing peptide of c-Myc (Lutterbach and Hann, 1994) whereas peptide C migrated more negatively in the ®rst dimension. There could be several explanations for these results. Firstly, peptide C could merely be a phosphoSer-68 containing partial digestion product. Secondly, peptide C could be doubly phosphorylated at Ser-68 and a second unknown site, which might explain its negative migration, with phosphorylation of the second site being dependent on Ser-68 phosphorylation. Thirdly, peptide C could represent a single unknown phosphorylation event that is dependent on Ser-68 phosphorylation. Lastly, peptide C may contain only Ser-68 phosphorylation but have some other additional modi®cation which alters its migration. A phosphopeptide which migrates similarly to peptide C is sometimes observed in peptide maps of c-Myc and phosphoamino acid analysis showed this peptide contains phosphoserine (Lutterbach and Hann, unpublished observations). B-Myc peptide maps did not appear to contain a phosphopeptide which could represent phosphorylation at Thr-56, homologous to Thr-58 of c-Myc, in MBI. This is somewhat surprising as Thr-58 is a major phosphorylation site in c-Myc, especially when c-Myc is overexpressed (Lutterbach and , and this region is conserved between c-Myc and B-Myc. It was recently shown that c-Myc is a substrate for phosphorylation by the stress-activated kinase JNK at Ser-62 and Ser-71 (Noguchi et al., 1999) . Thus, BMyc may also be subject to phosphorylation by JNK, at Ser-60 and Ser-68, which could serve to regulate BMyc activity in response to extracellular stress.
B-Myc as a growth inhibitor
c-Myc is a potent stimulator of cellular proliferation. Overexpression of c-Myc accelerates the growth of Rat 1a ®broblasts and induces transformation (Eilers et al., 1989; Xiao et al., 1998) . Moreover, c-Myc is essential for normal proliferation; homozygous inactivation of cmyc in Rat1 ®broblasts diminished their rate of proliferation 2 ± 3-fold (Mateyak et al., 1997) . In addition, downregulation of c-Myc expression is necessary for terminal dierentiation (Marcu et al., 1992) . In this study we have shown that, in contrast to c-Myc, overexpression of B-Myc signi®cantly slows the rate of proliferation of Rat 1a ®broblasts and COS cells. This could signify a biological role for B-Myc as an inhibitor of cellular proliferation. Consistent with this idea, high level B-Myc expression is restricted mainly to tissues with a low proliferative capacity and to cells of a more dierentiated phenotype. Thus, BMyc may play a role in inducing and maintaining a nonproliferative state in speci®c tissues. The mechanism which underlies B-Myc's ability to inhibit proliferation is open to speculation. Given that B-Myc is highly homologous to the transcriptional regulatory domain of c-Myc and opposes c-Myc function, a likely possibility is that B-Myc negatively regulates c-Myc and possibly other Myc family proteins by competitively binding and sequestering a cofactor(s) necessary for their ability to regulate gene transcription. Indeed, in a previous study, it was shown that B-Myc can inhibit the ability of a GAL4/c-Myc chimera to activate transcription as well as the ability of c-Myc to transform rat embryo ®broblasts in cooperation with Ras (Resar et al., 1993) . As B-Myc and c-Myc are not always expressed in the same tissues, B-Myc may antagonize other growth promoting transcription factors, in addition to c-Myc, by competing for a common cofactor(s). One candidate for such a factor is TRRAP, a recently identi®ed nuclear cofactor which binds the c-Myc N-terminal domain in a MBIIdependent manner and is essential for the oncogenic activity of c-Myc as well as the E2F transcription factor (McMahon et al., 1998) . It will be of interest to identify proteins which interact with B-Myc in order to elucidate the mechanism by which B-Myc inhibits cellular proliferation.
Materials and methods
Plasmids
The B-myc cDNA clone was isolated from a mouse embryonic expression library (Clontech). DNA sequencing veri®ed the murine B-myc sequence previously reported by Asker et al. (1995) . An approximately 600 kb insert containing the entire murine B-myc open reading frame was cloned into the cytomegalovirus (CMV) promoter-driven expression plasmid pcDNA3 (Invitrogen), to generate CMV-B-Myc, and into the retroviral vector pBabe(puro) to generate pBabe-BMyc. Single-stranded DNA from CMV-B-Myc was used to create the S60A and S68A mutations by site-directed mutagenesis according to the method of Kunkel (1985) and mutations were veri®ed by DNA sequencing. The CMVhemagglutinin (HA) epitope-tagged ubiquitin expression plasmid (pMT123) has been described previously (Treier et al., 1994) and was a gift from G Kato (Johns Hopkins University).
Cell lines
COS-7 African green monkey kidney cells, NIH3T3 mouse embryo ®broblasts, Rat 1a rat embryo ®broblasts and the ecotropic packaging cell line c2 were maintained in Dulbecco's modi®ed Eagle medium (DMEM, high glucose; Gibco-BRL) containing 10% calf serum (Hyclone). LbT2 and aT3-1 mouse gonadotrope cells were a gift from P Mellon (University of California at San Diego, San Diego, CA, USA) and were maintained in DMEM containing 5% fetal calf serum (Hyclone) and 5% calf serum. GH-3 somatotrope/ lactotrope cells were obtained from American Type Culture Collection and were maintained in DMEM containing 10% fetal calf serum. DMEM was supplemented with 100 U/ml penicillin and 100 mg/ml streptomycin. All cell lines were maintained at 378C in a humidi®ed 5% CO 2 atmosphere. To generate stable Rat 1a ®broblast cell lines, c2 cells were transfected with pBabe-B-Myc or empty pBabe(puro) using the calcium phosphate precipitation method as previously described (Spotts et al., 1997) and virus-producing cell lines were selected in 2.5 mg/ml puromycin. The dierent viral media were used to infect Rat 1a cells in the presence of 6 mg/ ml polybrene for 6 h and stable cell lines were selected in 2.5 mg/ml puromycin for 2 weeks. Early passage cell lines were used for growth curve analysis as described in the text. To generate the stable COS-7 cell line, COS-7 cells were transfected with CMV-B-Myc using the calcium phosphate precipitation method and selected in 400 mg/ml G418. After the initial selection (3 weeks), the cells were maintained in 250 mg/ml G418.
Northern blot analysis
Total RNA was isolated from tissues dissected from adult ICR mice or isolated from cell lines using Trizol reagent (Gibco-BRL). Ten mg of RNA per lane was separated on a 1% agarose-formaldehyde gel and transferred to a nylon membrane (Nytran, Schleicher and Schuell). The blots were prehybridized for 2 h at 428C in hybridization buer (50% formamide, 56SSC, 0.2 mg/ml salmon sperm DNA, 0.4 mg/ ml yeast RNA, 50 mg/ml BSA, 0.1% SDS, and 12.5 mM sodium phosphate buer, pH 6.6) followed by hybridization with 32 P-labeled cDNA probe (3610 5 c.p.m./ml hybridization buer) overnight at 428C. cDNA probes for murine B-myc, human c-myc, and 18S rRNA were prepared by random primer labeling (Prime-It, Stratagene) of cDNA fragments. The blots were washed in 26SSC at room temperature for 10 min followed by washing in 26SSC, 1% SDS at 428C for 30 ± 45 min and then at 658C prior to exposure to ®lm.
Antibodies
The murine B-myc cDNA encoding the C-terminal 50 amino acids of B-Myc was PCR ampli®ed and cloned into the BamH1 site of pGEX-2T (Pharmacia Biotech) which fused glutathione S-transferase (GST) in frame to the N-terminus of the protein. The fusion protein, GST-B-Myc50C, was expressed in BL21 E. Coli and puri®ed on glutathione agarose (Sigma) as described by Smith and Johnson (1988) . Puri®ed GST-B-Myc50C was used for the generation of anity-puri®ed rabbit polyclonal antiserum, anti-B-Myc50C, as previously described (Hann et al., 1983) . The rabbit polyclonal antiserum, anti-MycN100 (against the N-terminal 100 amino acids of murine c-Myc), was generated as described previously (Lutterbach and Hann, 1994) . Mouse monoclonal anti-HA (12CA5) was obtained from A Reynolds (Vanderbilt University).
Immunoprecipitation analysis
Cells were lysed in cold Ab lysis buer (Hann et al., 1983) with 20 U/ml aprotinin (Sigma) followed by sonication. For radiolabeled cells, the amount of radiolabel incorporated into cellular proteins was determined by precipitation with 10% trichloroacetic acid (TCA). Equivalent amounts of TCAprecipitable counts from each cellular lysate were adjusted to equal volumes with Ab buer, precleared with Staphylococcus aureus membranes (Pansorbin, Calbiochem), and clari®ed by centrifugation. Lysates were then incubated with 5 mg of the indicated antibody for 1 ± 2 h at 48C, and the immune complexes were precipitated with Pansorbin for 20 min. The immunoprecipitates were washed three times with cold RIPA buer (Hann et al., 1983) and incubated at 958C for 3 min in Laemmli sample buer. Samples were subjected to sodiumdodecyl sulfate polyacrylamide gel electrophoresis (SDS ± PAGE) using 12.5 or 15% polyacrylamide gels followed by autoradiography. High-range protein molecular weight markers (Gibco-BRL) were used as standards in each SDS ± PAGE gel.
Western blot analysis
Tissues dissected from adult ICR mice were homogenized and lysed in cold RIPA buer (Hann et al., 1983) with 3% aprotinin and 0.1 mg/ml PMSF. Cultured cells were lysed in cold RIPA buer. Protein concentrations of lysates were determined using the DC protein assay (Bio-Rad). Equal amounts of lysate (100 mg total protein) were boiled for 3 min in Laemmli sample buer and subjected to 12.5 or 15% SDS ± PAGE. High-range molecular weight markers (Rainbow markers, Amersham) were used as standards in each SDS ± PAGE gel. Proteins were then electrophoretically transferred to nitrocellulose membranes (Protran, Schleicher and Schuell) followed by blocking in milk buer [3% milk in Tris-buered saline (TBS), pH 7.5] and incubation with the indicated primary antibody in milk buer overnight at 48C. Anti-B-Myc50C was used at 10 mg/ml and anti-HA was used at 2.5 mg/ml. The membranes were washed using TBS (pH 7.5) and proteins were detected by incubation with horseradish peroxidase (HRP)-conjugated donkey anti-rabbit IgG (Jackson Laboratories) at 1 : 30 000 or goat anti-mouse IgG (Amersham) at 1 : 40 000, as appropriate, followed by enhanced chemiluminescence (ECL; Amersham) according to the manufacturer's instructions.
Subcellular fractionation
COS-7 cells stably transfected with CMV-B-Myc at a density of 1610 7 per 100 mm plate were labeled with 600 mCi 35 Smethionine/cysteine (Trans 35 S-label, ICN) in methionine/ cysteine-free DMEM (Gibco-BRL) for 20 min. Cells were incubated for an additional 10 min in media without label at 378C, washed with phosphate-buered saline (PBS, pH 7.2), trypsinized, pelleted and resuspended in cold hypotonic buer (10 mM HEPES, pH 7.9, 10 mM KCl, 1.5 mM MgCl 2 , 0.5 mM DTT, 0.2 mM PMSF, and 20 U/ml aprotinin). Cells were allowed to swell on ice for 10 min and lysed by 20 strokes in a prechilled Dounce homogenizer. Microscopy was used to verify that lysis was complete and nuclei remained intact. The nuclei were pelleted by centrifugation at 500 g for 5 min at 48C. The supernatant, representing the cytoplasmic fraction, was clari®ed at 10 000 g to remove contaminating debris. The nuclei were washed twice in hypotonic buer, resuspended in hypotonic buer containing 0.5% Triton X-100 and 0.1% deoxycholate (DOC), and incubated on ice 15 min. The nuclei were centrifuged at 500 g for 5 min at 48C and the resultant supernatant represented the nucleoplasmic fraction. The nuclei were then washed once in hypotonic buer containing 0.5% Triton X-100 and 0.1% DOC and the ®nal pellet represented the nuclear fraction. All three fractions (cytoplasmic, nucleoplasmic, and nuclear) were adjusted to 0.5% Triton X-100, 0.1% DOC and 0.5% SDS, sonicated brie¯y, clari®ed at 10 000 g, and subjected to immunoprecipitation analysis.
Phosphopeptide mapping analysis
COS-7 cells at a density of 4610 6 cells per 100 mm plate were transiently transfected with 5 mg CMV-B-Myc (wildtype) or B-Myc with the indicated mutation. Forty-eight hours post-transfection, the cells were labeled with 2 mCi 32 Porthophosphate (ICN) per plate in phosphate-free DMEM (Cellgro) for 45 min. 32 P-labeled B-Myc was immunoprecipitated using anti-B-Myc50C, fractionated by 15% SDS ± PAGE, and transferred to nitrocellulose. B-Myc was digested o the membrane with 10 mg thermolysin (Worthington), followed by performic acid oxidation, and repeated lyophilization as previously described (Lutterbach and Hann et al., 1994) . The digested peptides were separated on thin layer cellulose plates (EM Science), in the ®rst dimension by electrophoresis using a Hunter thin layer electrophoresis chamber in pH 1.9 buer (1.5 kV, 20 min), and separated in the second dimension by ascending chromatography in phosphochromatography buer (15 h) as previously described (Lutterbach and Hann, 1994) .
